Iltefat Hamzavi, MD: Combining Phototherapy with Topical Therapy in Patients with Vitiligo
Iltefat Hamzavi, MD, and JCAD’s Editor-in-Chief, James Del Rosso, DO, discuss topical treatment considerations for patients with vitiligo when using topical ruxolitinib cream, including topical treatment in patients with extensively affected areas and combining topical ruxolitinib with phototherapy. Read the full exchange and additional patient details, in JCAD’s recent supplement—Vitiligo Exchange: An Expert Panel Discussion […]
David Rosmarin, MD: Updates in Topical and Systemic Vitiligo Treatment
Dr. Rosmarin discusses his vitiligo session from November’s Masterclasses in Dermatology Meeting, in which he reviewed recent insights on maintaining and building upon initial treatment response with long-term use of ruxolitinib cream as well as oral JAKs on the horizon for vitiligo.
Nada Elbuluk, MD: Psychological Comorbidity Assessment and Counseling for Patients with Vitiligo
Dr. Elbuluk discusses the importance of assessing the psychological state of patients by gathering social information such as daily activities, living situation, and work status.1 Reference: Disclosures: Expert Perspectives in Vitiligo is supported by InCyte. Dr. Elbuluk has served as a consultant and advisory board member for InCyte. However, the study discussed by Dr. Elbuluk […]
James Del Rosso, DO: Discussing Early Immune Activity Upon Ruxolitinib Cream Withdrawal
Dr. Del Rosso, JCAD’s Clinical Editor-in-Chief, reviews a poster presented by Volkova et al at the 2024 American Academy of Dermatology annual meeting. The poster presented findings from the TRuE-V long-term extension (LTE) study, which evaluated changes in serum biomarkers in patients with segmental vitiligo who were randomized in the LTE to apply the vehicle or continue using ruxolitinib 1.5% cream after both groups had used ruxolitinib cream in the parent studies.
Nada Elbuluk, MD: Connecting Patients with Vitiligo with Supportive Resources
Dr. Elbuluk discusses the importance of connecting patients with vitiligo to supportive resources for preventing and mitigating anxiety and depression related to the condition, especially socioeconomically disadvantaged patients who may not be aware of these resources in their community.